RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $101
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on Edwards Lifesciences (EW) and raises the price target from $95 to $101.
April 15, 2024 | 6:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained its Outperform rating on Edwards Lifesciences and increased the price target from $95 to $101.
The upgrade in the price target by RBC Capital suggests a positive outlook on Edwards Lifesciences' stock, likely due to strong company fundamentals or market position. This analyst endorsement can lead to increased investor confidence and potential stock price appreciation in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100